PEAK6’s Procept Biorobotics PRCT Stock Holding History

PEAK6’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$603K	Buy	+33,100	New	+$660K	﹤0.01%	1781

Other funds holding PRCT

BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Champlain Investment Partners Burlington, Vermont $2.9B AUM 23.58% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Rhenman & Partners Asset Management Stockholm, Sweden $903M AUM 49.67% 1-Year Est. Return

PEAK6's PRCT Position: Q3 2026 in Review

PEAK6 opened a new position in Procept Biorobotics (PRCT) in Q3 2026: 3,238 shares worth $59K. The stake represents ﹤0.01% of the portfolio and ranks #2328 among its holdings.

139 funds tracked by Wall St. Rank hold PRCT as of Q3 2026.

PEAK6 held 3,238 shares of Procept Biorobotics worth $59K as of Q3 2026.
Procept Biorobotics was a new PEAK6 position in Q3 2026.
Procept Biorobotics made up ﹤0.01% of PEAK6's portfolio in Q3 2026, its #2328 holding.
139 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2026.

Based on PEAK6's 13F filing for Q3 2026, filed 13 Nov 2026.